Aerie Pharmaceuticals Inc (AERI) was Reiterated by RBC Capital Mkts to “Outperform” according to the research note released today. The brokerage firm has raised the Price Target to $ 55 from a previous price target of $51 . RBC Capital Mkts advised their investors in a research report released on Sep 15, 2016.
Many Wall Street Analysts have commented on Aerie Pharmaceuticals Inc. Aerie Pharmaceuticals Inc was Initiated by Raymond James to “Strong Buy” on Sep 14, 2016.
Aerie Pharmaceuticals Inc opened for trading at $21.15 and hit $21.99 on the upside on Wednesday, eventually ending the session at $21.13, with a gain of 7.53% or 1.48 points. The heightened volatility saw the trading volume jump to 3,587,001 shares. Company has a market cap of $589 M.
In a different news, on Apr 26, 2016, Gerald D. Cagle (director) purchased 4,646 shares at $18.24 per share price. According to the SEC, on Apr 16, 2015, Anand Mehra (director) sold 425,000 shares at $33.76 per share price.
Aerie Pharmaceuticals Inc. is a clinical-stage pharmaceutical company. The Company is engaged in the discovery development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s primary product candidates triple-action Rhopressa and quadruple-action Roclatan are once-daily eye drops. The Company’s product candidate once-daily quadruple-action Roclatan is a single drop fixed-dose combination of Rhopressa and latanoprost. Rhopressa inhibits Rho Kinase (ROCK) and the norepinephrine transporter (NET) which are both biochemical targets for lowering intraocular pressure (IOP). The Company’s Rhopressa product candidate was in Phase III stage of development. The Company has completed the Roclatan Phase IIb clinical trial. The Company is also in the preclinical development stage with AR-13533 its second-generation ROCK/NET inhibitor.